ArticleBlood advances2017
Patient-derived antibody recognizes a unique CD43 epitope expressed on all AML and has antileukemia activity in mice.
Article in Blood advances, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Next-generation CAR-T therapy for acute myeloid leukemia: bridging innovation with clinical translation.Annals of hematology · 2026Review
- Sialylated CD43 is a glyco-immune checkpoint for macrophage phagocytosis.bioRxiv : the preprint server for biology · 2025Article
- Article
- Cluster of Differentiation Markers and Human Leukocyte Antigen Expression in Chronic Lymphocytic Leukemia Patients: Correlations and Clinical Relevance.Current issues in molecular biology · 2024Article
- Apoptosis-mediated ADAM10 activation removes a mucin barrier promoting T cell efferocytosis.Nature communications · 2024Article
- Clinical Significance of Uncommon, Non-Clinical, and Novel Autoantibodies.ImmunoTargets and therapy · 2024Review
- Autoantibodies to Interferons in Infectious Diseases.Viruses · 2023Review
- The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML.Blood advances · 2023Article
- High-throughput identification of autoantibodies that target the human exoproteome.Cell reports methods · 2022Article
- Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo.Cancer immunology, immunotherapy : CII · 2021Article
- Review
- Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia.Journal for immunotherapy of cancer · 2021Article
- Tumour-reactive B cells and antibody responses after allogeneic haematopoietic cell transplantation.Immuno-oncology technology · 2020Review
- Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond.Children (Basel, Switzerland) · 2020Review
- Genome-scale CRISPR activation screen uncovers tumor-intrinsic modulators of CD3 bispecific antibody efficacy.Scientific reports · 2019Article
- Immunotherapy for acute myeloid leukemia: from allogeneic stem cell transplant to novel therapeutics.Leukemia & lymphoma · 2019Review
- Survival of early posthematopoietic stem cell transplantation relapse of myeloid malignancies.European journal of haematology · 2019Article
- Coexpression of CD5 and CD43 predicts worse prognosis in diffuse large B-cell lymphoma.Cancer medicine · 2018Article
- Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.Frontiers in oncology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy has proven beneficial in many hematologic and nonhematologic malignancies, but immunotherapy for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) is hampered by the lack of tumor-specific targets. We took advantage of the tumor-immunotherapeutic effect of allogeneic hematopoietic stem cell transplantation and searched the B-cell repertoire of a patient with a lasting and potent graft-versus-AML response for the presence of AML-specific antibodies. We identified an antibody, AT1413, that was of donor origin and that specifically recognizes a novel sialylated epitope on CD43 (CD43s). Strikingly, CD43s is expressed on all World Health Organization 2008 types of AML and MDS. AT1413 induced antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of AML cells in vitro. Of note, AT1413 was highly efficacious against AML cells in a humanized mouse model without affecting nonmalignant human myeloid cells, suggesting AT1413 has potential as a therapeutic antibody.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.